ClinicalTrials.gg

Program

Partially Engineered T-regulatory Cell Donor Graft TRGFT-201

Its studies are mostly in Leukemia, Myeloid, Acute, led by Orca Biosystems.

Furthest: phase 3, since Mar 30, 20223 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Orca Biosystems33 open or runningphase 3since Mar 30, 2022Jul 3, 2019Nov 2027phase 2 · NCT07216443

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 3, 2019First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT04013685 · 155 enrolled · United States
  2. Mar 30, 2022Phase 3 study in Leukemia, Myeloid, AcuteNCT05316701 · 187 enrolled · United States
  3. Sep 29, 2025Phase 2 study in Leukemia, Myeloid, AcuteNCT07216443 · 80 planned · United States

Ahead

  1. Nov 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT07216443

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07216443Leukemia, Myeloid, Acute · United States2RecruitingNov 202780
NCT05316701Leukemia, Myeloid, Acute · United States3Active, not recruitingJul 15, 2024187
NCT04013685Leukemia, Myeloid, Acute · United States1Active, not recruitingApr 30, 2025155

How it is read

Names in the registry

  • “Orca-T”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.